On February 26, 2026, The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with……
On February 02, 2026--Tenpoint Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.2%, previously known as BRIMOCHOL™……
On February 26, 2026, The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with……
On February 02, 2026--Tenpoint Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.2%, previously known as BRIMOCHOL™……
Oct. 27, 2025 -- Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus®, the only oral GLP-2 medication available, for reducing the risk of major adverse cardiovascular events ……
Sep. 30, 2025 -- Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain ……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
